PP-405

PP-405 is a first-in-class, topically administered small-molecule inhibitor of the mitochondrial pyruvate carrier (MPC), under clinical development by Pelage Pharmaceuticals for the treatment of androgenetic alopecia (AGA) in men and women. The compound acts as a dual inhibitor of MPC1 and MPC2, blocking pyruvate import into the mitochondrial matrix and thereby redirecting cellular metabolism toward glycolysis with concomitant elevation of intracellular lactate through stimulation of lactate dehydrogenase (LDH) activity. This metabolic shift activates quiescent hair follicle stem cells (HFSCs) residing in the bulge region of the hair follicle, driving telogen-to-anagen transition and the initiation of new hair growth cycles. The mechanistic rationale derives from the seminal Flores et al. (2017) demonstration in Nature Cell Biology that HFSCs utilize glycolytic metabolism, produce substantially more lactate than other epidermal cell populations, and that genetic deletion of lactate dehydrogenase A (Ldha) prevents HFSC activation, while genetic deletion of mitochondrial pyruvate carrier 1 (Mpc1) accelerates the hair cycle in murine models [1]. The medicinal chemistry program at UCLA, led by Michael Jung in collaboration with Heather Christofk and William Lowry, subsequently developed a series of novel MPC inhibitors based on the cyano-cinnamate pharmacophore, advancing from the prototype UK-5099 through iterative structure-activity relationship optimization to produce compounds with markedly enhanced potency and skin-penetration characteristics [2].

PP-405 is the proprietary clinical candidate selected from this program. Its chemical structure has not been publicly disclosed; Pelage Pharmaceuticals has confirmed that PP-405 is structurally distinct from JXL-069, the published 7-azaindole-bearing MPC inhibitor (CAS 2260696-63-5) described in the Jeong et al. (2021) Journal of Medicinal Chemistry report, though both compounds originate from the same UCLA medicinal chemistry effort [2, 3]. The compound has been engineered for preferential skin penetration over systemic absorption, with reported selectivity of approximately 1,000-fold for dermal over plasma distribution. In clinical pharmacokinetic assessments, no PP-405 was detected in circulating blood plasma following topical scalp application at the clinical dose of 0.05%, and the compound is reported to be unstable in blood, providing an intrinsic pharmacokinetic safety margin against systemic exposure [4, 5].

Clinical development has proceeded through a Phase 1 safety and pharmacokinetic study completed in January 2024 and a Phase 2a randomized, multicenter, double-blind, vehicle-controlled efficacy trial (NCT06393452) in 78 adults with androgenetic alopecia. The Phase 1 study demonstrated proof of mechanism through scalp biopsy analysis showing statistically significant upregulation of Ki67-positive proliferating cells in the hair follicle bulge region after seven days of 0.05% PP-405 topical application, with concurrent increases in LDH activity in hair follicle stem cells [4]. Ex vivo human scalp tissue experiments presented at the American Academy of Dermatology 2024 Annual Meeting confirmed that single topical applications of PP-405 at concentrations as low as 0.006% increased LDH activity in HFSCs within 24 hours [4]. The Phase 2a trial reported that 31% of PP-405-treated men with higher-grade hair loss demonstrated greater than 20% increases in hair density at eight weeks following four weeks of daily treatment, compared with 0% in the vehicle-control group; additionally, PP-405 induced new hair growth in areas where no hair was previously present, suggesting regenerative capacity beyond the follicle-preserving activity of existing therapies [5, 6]. The compound was well tolerated with no treatment-related systemic adverse events and no detectable systemic absorption.

Pelage Pharmaceuticals plans to initiate Phase 3 registration trials in 2026 to evaluate the safety and efficacy of PP-405 in both men and women with androgenetic alopecia. If successful, regulatory approval could be anticipated in the 2027 to 2029 timeframe. This monograph reviews the discovery and development history, the metabolic mechanism of action in molecular and cellular detail, the available pharmacokinetic and pharmacodynamic data, the preclinical and clinical evidence base, sourcing and handling considerations for the research-grade precursor compound JXL-069, stack-interaction considerations, adverse-event and safety data, and a comparative assessment of five alternative androgenetic alopecia therapies (minoxidil, finasteride, dutasteride, clascoterone, pyrilutamide) against PP-405 on five competency standards.